The study objective is to describe and quantify the incidence of treatment-induced late effects in AYA lymphoma patients.
Consecutive patients diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) at 15–24 years of age were identified. All patients in British Columbia who received radiation therapy (RT) from 1974 to 2014 with ≥ 5-year survival post-RT were included. Late effects’ analyses included only survivors who received RT to the relevant anatomical site(s) and/or relevant chemotherapy, and were reported as cumulative incidence (CI) ± standard error.
Three hundred and five patients were identified (74% HL). Median age of diagnosis was 21 years. Median follow-up was 19.1 years for secondary malignancy and 7.2 years for other endpoints. Hypothyroidism was the most prevalent late effect, with a CI of 22.4 ± 2.8% and 35.1 ± 4% at 5 and 10 years, respectively. CI of in-field secondary malignancy was 0.4 ± 0.4% at 10 years and 2.8 ± 1.2% at 20 years. CI of symptomatic pulmonary toxicity was 4.6 ± 1.5% and 6.8 ± 2.0% at 5 and 10 years, respectively, and was higher in patients receiving multiple RT courses (p = 0.009). Esophageal complications occurred at a CI of 1.4 ± 0.8% at 5 years and 2.2 ± 1.1% at 10 years. CI of xerostomia/dental decay was 2.6 ± 1.3% at 5 years and 4.9 ± 2.1% at 10 years. CI of cardiac disease was at 2.3 ± 0.9% at 5 years and 4.4 ± 1.5% at 10 years. CI of infertility was 6.5 ± 1.6% at 5 years and 9.4 ± 2.1% at 10 years.
Survivors of AYA lymphoma have a high incidence and diverse presentation of late effects.
Implications for Cancer Survivors
AYA lymphoma survivors should be educated about their risks of late effects and offered screening and follow-up when appropriate.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Olsson DS, Andersson E, Bryngelsson I-L, Nilsson AG, Johannsson G. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab. 2015;100(2):467–74. https://doi.org/10.1210/jc.2014-3525.
Palmer S, Mitchell A, Thompson K, Sexton M. Unmet needs among adolescent cancer patients: a pilot study. Pall Supp Care. 2007;5(2):127–34. https://doi.org/10.1017/S1478951507070198.
Nass SJ, Beaupin LK, Demark-Wahnefried W, Fasciano K, Ganz PA, Hayes-Lattin B, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine Workshop. Oncologist. 2015;20(2):186–95. https://doi.org/10.1634/theoncologist.2014-0265.
Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer. 2009;45(6):992–1005. https://doi.org/10.1016/j.ejca.2008.11.042.
Barthel EM, Spencer K, Banco D, Kiernan E, Parsons S. Is the adolescent and young adult cancer survivor at risk for late effects? It depends on where you look. J Adolesc Young Adult Oncol. 2016;5(2):159–73. https://doi.org/10.1089/jayao.2015.0049.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41. https://doi.org/10.3322/caac.21149.
Gupta S. Adolescents and young adults with cancer and the risk of subsequent primary neoplasms: not just big children. Lancet Oncol. 2019;20(4):466–7. https://doi.org/10.1016/S1470-2045(18)30941-0.
Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute–supported resource for outcome and intervention research. J Clin Oncol. 2009;27(14):2308–18. https://doi.org/10.1200/JCO.2009.22.3339.
Youn P, Milano MT, Constine LS, Travis LB. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer. 2014;120(15):2334–42. https://doi.org/10.1002/cncr.28733.
Oeffinger KC, Tonorezos ES. The cancer is over, now what? Cancer. 2011;117(S10):2250–7. https://doi.org/10.1002/cncr.26051.
Young people’s cancers incidence statistics. Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/young-people-cancers/incidence#ref-2. Published June 12, 2019. Accessed 4 Jan 2020.
Geiger AM, Castellino SM. Delineating the age ranges used to define adolescents and young adults. J Clin Oncol. 2011;29(16):e492–3. https://doi.org/10.1200/JCO.2011.35.5602.
Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, et al. Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Cancer. 2016;122(7):988–99. https://doi.org/10.1002/cncr.29870.
Hay AE, Rae C, Fraser GA, Meyer RM, Abbott LS, Bevan S, et al. Accrual of adolescents and young adults with cancer to clinical trials. Curr Oncol. 2016;23(2):81–6. https://doi.org/10.3747/co.23.2925.
McBride ML, Rogers PC, Sheps SB, et al. Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics. Pediatr Blood Cancer. 2010;55(2):324–30. https://doi.org/10.1002/pbc.22476.
Lo AC, Samuel V, Chen B, Savage KJ, Freeman C, Goddard K (2020) Evaluation of the discussion of late effects and screening recommendations in survivors of adolescent and young adult (AYA) lymphoma. https://doi.org/10.1007/s11764-020-00922-7.
Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12(21):6487–93. https://doi.org/10.1158/1078-0432.CCR-06-1420.
Morgan GW, Freeman AP, McLean RG, Jarvie BH, Giles RW. Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol. 1985;11(11):1925–31. https://doi.org/10.1016/0360-3016(85)90273-1.
Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: an emerging field. J Clin Oncol. 2010;28(32):4781–2. https://doi.org/10.1200/JCO.2010.30.5128.
Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97(3):663–73. https://doi.org/10.1002/cncr.11095.
Angelini P, Rodriguez L, Zolaly M, Naqvi A, Weitzman S, Abla O, et al. Outcome and toxicity patterns in children and adolescents with non-Hodgkin lymphoma: a single institution experience. Mediterr J Hematol Infect Dis. 2017;10(1):e2018020–8. https://doi.org/10.4084/mjhid.2018.020.
Bhakta N, Liu Q, Yeo F, Baassiri M, Ehrhardt MJ, Srivastava DK, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016;17(9):1325–34. https://doi.org/10.1016/S1470-2045(16)30215-7.
Materazzo C, Massimino M, Schiavello E, Podda M, Gandola L, Cefalo G, et al. Clinical and subclinical cardiac late effects in pediatric Hodgkin’s lymphoma survivors. Tumori J. 2017;103(6):566–71. https://doi.org/10.5301/tj.5000670.
Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer. 1984;53(4):878–83. https://doi.org/10.1002/1097-0142(19840215)53:4<878::aid-cncr2820530411>3.0.co;2-j.
Aleman BMP, Raemaekers JMM, Tirelli U, Bortolus R, van 't Veer M, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–406. https://doi.org/10.1056/NEJMoa022628.
Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618–29. https://doi.org/10.1093/jnci/93.8.618.
Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723–8. https://doi.org/10.1210/jc.2006-0020.
Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary complications in survivors of childhood and adolescent cancer. Cancer. 2002;95(11):2431–41. https://doi.org/10.1002/cncr.10978.
Hahn E, Jiang H, Ng A, Bashir S, Ahmed S. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol. 2017;98(5):1116–23. https://doi.org/10.1016/j.ijrobp.2017.03.026.
Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86. https://doi.org/10.1182/blood-2006-07-034405.
Freyer DR. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol. 2010;28(32):4810–8. https://doi.org/10.1200/JCO.2009.23.4278.
Sadak KT, Neglia JP, Freyer DR, Harwood E. Identifying metrics of success for transitional care practices in childhood cancer survivorship: a qualitative study of survivorship providers. Pediatr Blood Cancer. 2017;64(11):e26587. https://doi.org/10.1002/pbc.26587.
Bjøro T, Holman J, Krüger Ø, Midthjell K. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trùndelag (HUNT). Eur J Endocrinol. 2000;143:639–47.
Andersson A, Näslund U, Tavelin B, Enblad G, Gustavsson A, Malmer B. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors-retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124(8):1914–7. https://doi.org/10.1002/ijc.24147.
Chiu M, Austin PC, Manuel DG, Tu JV. Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. Can Med Assoc J. 2010;182(8):E301–10. https://doi.org/10.1503/cmaj.091676.
Cionini L, Pacini P, De Paola E, et al. Respiratory function tests after mantle irradiation in patients with Hodgkin’s disease. Acta Radiol Oncol. 1984;23(6):401–9. https://doi.org/10.3109/02841868409136039.
Salloum E, Tanoue LT, Wackers FJ, Zelterman D, Hu GL, Cooper DL. Assessment of cardiac and pulmonary function in adult patients with Hodgkin’s disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Cancer Investig. 1999;17(3):171–80. https://doi.org/10.3109/07357909909021418.
Smith LM, Mendenhall NP, Cicale MJ, Block ER, Carter RL, Million RR. Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol. 1989;16(1):79–84. https://doi.org/10.1016/0360-3016(89)90013-8.
Shapiro SJ, Shapiro SD, Mill WB, Campbell EJ. Prospective study of long-term pulmonary manifestations of mantle irradiation. Int J Radiat Oncol Biol. 1990;19(3):707–14. https://doi.org/10.1016/0360-3016(90)90500-j.
Villani F, Viviani S, Bonfante V, De Maria P, Soncini F, Laffranchi A. Late pulmonary effects in favorable stage I and IIA Hodgkin’s disease treated with radiotherapy alone. Am J Clin Oncol. 2000;23(1):18–21. https://doi.org/10.1097/00000421-200002000-00004.
Villani F, De Maria P, Bonfante V, et al. Late pulmonary toxicity after treatment for Hodgkin’s disease. Anticancer Res. 1997;17(6D):4739–42.
Hassink EA, Souren TS, Boersma LJ, et al. Pulmonary morbidity 10-18 years after irradiation for Hodgkin’s disease. Eur J Cancer. 1993;29A(3):343–7. https://doi.org/10.1016/0959-8049(93)90382-p.
Lund MB, Kongerud J, Nome O, Abrahamsen AF, Bjπrtuft Ø, Forfang K, et al. Lung function impairment in long-term survivors of Hodgkin’s disease. Ann Oncol. 1995;6(5):495–501. https://doi.org/10.1093/oxfordjournals.annonc.a059221.
Ellenhorn JDI, Lambroza A, Lindsley KL, Laquaglia MP. Treatment-related esophageal stricture in pediatric patients with cancer. Cancer. 1993;71(12):4084–90. https://doi.org/10.1002/1097-0142(19930615)71:12<4084::AID-CNCR2820711246>3.0.CO;2-B.
Mahboubi S, Silber JH. Radiation-induced esophageal strictures in children with cancer. Eur Radiol. 1997;7(1):119–22. https://doi.org/10.1007/s003300050123.
Marangoni-Lopes L, Rodrigues LP, Mendonca RH, Nobre-dos SM. Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease. Arch Oral Biol. 2016;72:99–105. https://doi.org/10.1016/j.archoralbio.2016.08.023.
Chang DT, Amdur RJ, Pacholke H, Mendenhall NP, Morris CG, Byer GA, et al. Xerostomia in long-term survivors of aggressive non-Hodgkin’s lymphoma of Waldeyer’s ring: a potential role for parotid-sparing techniques? Am J Clin Oncol. 2009;32(2):145–9. https://doi.org/10.1097/COC.0b013e3181841f42.
Rodrigues NA, Killion L, Hickey G, Silver B, Martin C, Stevenson MA, et al. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. Int J Radiat Oncol Biol. 2009;75(4):1079–83. https://doi.org/10.1016/j.ijrobp.2008.12.053.
Koh E-S, Tran T, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2(1):13–1. https://doi.org/10.1186/1748-717X-2-13.
Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–8. https://doi.org/10.1093/annonc/mdt156.
Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2012;23(5):1259–66. https://doi.org/10.1093/annonc/mdr439.
Maraldo MV, Jørgensen M, Brodin NP, Aznar MC, Vogelius IR, Petersen PM, et al. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer. 2013;61(4):717–22. https://doi.org/10.1002/pbc.24861.
De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–46. https://doi.org/10.1200/JCO.2008.19.9174.
Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17(12):1749–60. https://doi.org/10.1093/annonc/mdl302.
Draube A, Behringer K, Diehl V. German Hodgkin’s Lymphoma Study Group trials: lessons from the past and current strategies. Clin Lymphoma Myeloma. 2011;6(6):458–68. https://doi.org/10.3816/CLM.2006.n.026.
Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2017;68(2):116–32. https://doi.org/10.3322/caac.21438.
Zhou R, Ng A, Constine LS, Stovall M, Armstrong GT, Neglia JP, et al. A comparative evaluation of Normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the childhood Cancer Survivor Study and Recent Children’s Oncology Group Trials. Int J Radiat Oncol Biol. 2016;95:1–5. https://doi.org/10.1016/j.ijrobp.2016.01.053.
Ansell SM. Maintaining efficacy but decreasing toxicity in the treatment of Hodgkin lymphoma. HemaSphere. 2017;1(1):e7–2. https://doi.org/10.1097/HS9.0000000000000007.
Children’s Oncology Group: long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 5.0. 2018:1–232. http://www.survivorshipguidelines.org/. Accessed 01 Sep 2020.
Conflict of interest
K.J.S received institutional research funding from Roche. C.F. has honoraria from Seattle Genetics, Janssen, Amgen, Celgene and Abbvie, and research funding from Roche and Teva. None of the other authors have conflicts of interest to disclose.
This study was approved by the University of BC / BC Cancer Research Ethics Board.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lo, A.C., Chen, B., Samuel, V. et al. Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis. J Cancer Surviv (2021). https://doi.org/10.1007/s11764-020-00976-7
- Radiation therapy
- Late effects
- Adolescent and young adult